Chemotherapy for Primary Liver Cancer: Recent Updates and Future Perspectives
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 May 2024 | Viewed by 1026
Special Issue Editor
Special Issue Information
Dear Colleagues,
Worldwide, primary liver cancer is the sixth most common type of cancer and the third most common cause of death, with hepatocellular carcinoma (HCC) accounting for approximately 80% and intrahepatic cholangiocarcinoma (CC) approximately 15% of histological types.
Systemic drug therapy for unresectable HCC has changed significantly since the approval of the multi-kinase inhibitor sorafenib. In 2017–2018, four drugs (regorafenib, lenvatinib, cabozantinib and ramucirumab) were approved. In 2020, the first immunotherapy for liver cancer, atezolizumab, a programmed death ligand 1 inhibitor (in combination with the VEGF inhibitor bevacizumab), was approved.
Intrahepatic CC has long been the first-line treatment for cytotoxic chemotherapy, especially the combination of gemcitabine and cisplatin, since 2010; in 2022, a regimen adding immunotherapy (durvalumab) to these two drugs was approved. For cases with mutations in the driver genes of the disease (fibroblast growth factor receptor 1/2/3, isocitrate dehydrogenase 1/2, neurotrophic tyrosine receptor kinase A/B/C etc.), we have precision medicine available to target these as second-line therapy.
Treatment options for HCC and intrahepatic CC have increased, and long-term survival has been achieved. On the other hand, countermeasures against immune-related adverse events have become necessary. We expect to further improve therapeutic outcomes by understanding that hepatocellular carcinoma has a variety of cellular origins and tumor microenvironments.
We invite you to contribute to this Special Issue on "Chemotherapy of Primary Liver Cancer". The purpose of this Special Issue is to collect articles highlighting recent advances in this theme. Original research articles and reviews are welcome in this Special Issue. Areas of research may include (but are not limited to) the following:
- Diagnosis of chemotherapy efficacy (including biomarkers and imaging techniques);
- Combination of locoregional therapy (transcatheter arterial chemoembolization or hepatic arterial infusion chemotherapy) and systemic drug therapy.
I look forward to receiving your contributions.
Dr. Etsushi Kawamura
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- primary liver cancer
- hepatocellular carcinoma
- cholangiocarcinoma
- cholangiocellular carcinoma
- hepatobiliary cancer
- bile duct cancer
